Cytosorbents (CTSO) Asset Writedowns and Impairment (2016 - 2026)
Cytosorbents' (CTSO) quarterly Asset Writedowns and Impairment came in at $300000.0 in Q1 2026, up 1204.35% on a QoQ basis from $23000.0 in Q4 2025.
Cytosorbents (CTSO) Asset Writedowns and Impairment (2016 - 2026) Analysis & Trends
Cytosorbents (CTSO) has 11 years of Asset Writedowns and Impairment data on file, last reported at $300000.0 in Q1 2026.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $300000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $340000.0 (up 296.46% YoY) and the FY2025 annual result came in at $40000.0, down 65.22% from the prior year.
- Asset Writedowns and Impairment advanced to $300000.0 in Q1 2026, from $23000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $462237.0 in Q3 2023 to a low of -$461187.0 in Q4 2023.
- A 5-year average of $69065.0 and a median of $20209.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment surged 6533.08% — and 2023, when it slumped 661.72%.
- Tracing CTSO's Asset Writedowns and Impairment over 5 years: stood at $204180.0 in 2022, then tumbled by 325.87% to -$461187.0 in 2023, then soared by 101.73% to $8000.0 in 2024, then jumped by 187.5% to $23000.0 in 2025, then jumped by 1204.35% to $300000.0 in 2026.
- The last three Asset Writedowns and Impairment figures came in at $300000.0 (Q1 2026), $23000.0 (Q4 2025), and $8000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn |
| 10 | Cytosorbents | 21.57 Mn | 17.16 Mn | 7.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38,000.00 |
| Jun 30, 2026 | 38,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 23,000.00 |
| Dec 31, 2025 | 23,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 78,000.00 |
| Sep 30, 2024 | 78,000.00 |
| Jun 30, 2024 | -240.00 |
| Jun 30, 2024 | -240.00 |
| Mar 31, 2024 | 29,240.00 |
| Mar 31, 2024 | 29,240.00 |
| Dec 31, 2023 | -461,187.00 |
| Dec 31, 2023 | -461,187.00 |